Advertisement

Advertisement

ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR

ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Issues in Oncology

Can Baseline Kidney Function Predict Chronic Kidney Disease After Cisplatin Treatment?

A population-based prognostic study published in JAMA Oncology found cisplatin treatment to be associated with a predictable decrease in the estimated glomerular filtration rate. According to Grant et al, their findings place patients with lower baseline kidney function at the highest risk for developing chronic kidney disease.

Breast Cancer

BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark

Patients with stage II or III breast cancer who participated in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after 1 year, whereas those in the education-only control group gained an average 1% of their baseline weight, according to a recent report published by Jennifer A. Ligibel, MD, FASCO, and colleagues in JAMA Oncology. The findings from the Breast Cancer Weight Loss (BWEL) clinical trial set the stage for ongoing research to determine whether weight loss after breast cancer treatment can reduce the risk of cancer recurrence and extend survival. 

 


Advertisement
Skin Cancer

Basal Cell Carcinoma: Early Research on a Novel Topical Fluorescent Imaging Technique

A topical fluorescent molecular contrast agent, PARPi-FL (a poly[adenosine diphosphate ribose] polymerase 1 [PARP1] inhibitor–targeted fluorescent contrast agent) detected basal cell carcinoma through intact skin in as little as 5 minutes in ex vivo human tissues, according to new preclinical research published by Ricanati et al in The Journal of Nuclear Medicine. Data confirmed that PARPi-FL is nontoxic to the skin and does not cause systemic side effects, making it a potential tool for the diagnosis and management of basal cell carcinoma.

 

Gastroesophageal Cancer

Pembrolizumab Plus Chemotherapy vs Chemotherapy in Advanced Gastric Cancers: Final Survival Analysis From KEYNOTE-585

As reported in the Journal of Clinical Oncology by Shitara et al, the final overall survival analysis from the phase III KEYNOTE-585 study showed a numeric—but statistically nonsignificant—benefit with pembrolizumab plus chemotherapy vs chemotherapy in perioperative therapy for patients with resectable, locally advanced gastric and gastroesophageal junction cancers.

 

Advertisement
Advertisement





More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Issues in Oncology

New Report Supports Overhaul of Cancer Drug Dosing

A new study calls for a paradigm shift in how cancer drug dosages are determined, concluding that the long-standing practice of using the “maximum tolerated dose” (MTD) may be outdated, harmful to patients, and ill-suited for modern cancer therapies. “The Totality of the Evidence: Optimizing...

Advertisement

How to Adapt to the Era of AI and the Changing Interactions With Patients: Lessons From a Low-Resource Setting

After 2 decades of practicing medicine across multiple disciplines and health systems, I’ve witnessed the dramatic transformation of patient-physician interactions, and none more dramatic than what I’m seeing in this era of artificial intelligence (AI) and its impact on cancer care. Early in my...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Lymphoma

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented at the 2025 European Hematology Association (EHA) Congress.1 Results...

Lung Cancer

Studies on EGFR Mutations and NRG1 Fusions Included in ASCO NSCLC Living Guideline Update

ASCO has issued a new update to its living guideline on treatment of stage IV non–small cell lung cancer (NSCLC) with driver alterations based on two recent studies.1 The update, which amends the most recent version published in February 2025, includes a discussion of osimertinib therapy options in ...

Adding Dendritic Cell Vaccination to Hepatocellular Carcinoma Therapy

Patients with intermediate-stage hepatocellular carcinoma who received a vaccine of dendritic cells in addition to transarterial chemoembolization (TACE) and preconditioning cyclophosphamide experienced longer progression-free survival than those who received cyclophosphamide and TACE alone. The...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Lymphoma

Emerging PD-1 Inhibitor Plus Chemotherapy Shows Efficacy in Second-Line Classical Hodgkin Lymphoma

The addition of the PD-1 inhibitor sintilimab to ICE (ifosfamide, carboplatin, and etoposide) chemotherapy appeared to significantly improve the complete remission rate and showed a trend toward improved progression-free survival in second-line classical Hodgkin lymphoma, according to Yuankai Shi,...

Advertisement

Identifying CNS Tumors With Multianalyte Cerebrospinal Fluid Test

A novel, multianalyte test has been developed to identify central nervous system cancers from small samples of cerebrospinal fluid (CSF). In findings published in Cancer Discovery, the study authors reported that the test, called CSF-BAM, achieved a sensitivity of 81% and a specificity of 100%....

ASCO Post X Feed
Social Media Hub by Everwall